ACTRN12612000434897招募中4 期
Compare the Urate lowering response of Febuxostat & Allopurinol in Hyperuricemic patients
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Subjects are capable of giving informed consent
- •All male or female adult patients between 18 to 65 years age
- •All male or female adult patients's Serum Creatinine should be= or > 2 mg/dl
- •All patients with Asymptomatic = or > 8 mg/dl of Serum Uric Acid
- •All patients with Symptomatic = or > 6.5 mg/dl of Serum Uric Acid
- •Physician is the final authority to consider the patient, who is eligible for the clinical trial.
排除标准
- •Known history of allergic with Febuxostat or Allopurinol
- •Patient with Ischaemic cardiac disease
- •Renal dysfunction (Serum Creatinine = 4 mg/dL)
- •Hepatic dysfunction
研究者
相似试验
已完成
不适用
Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemiaChronic heart failure patients with hyperuricemiaJPRN-UMIN000013330EAF-CHF steering committee200
招募中
不适用
effects of Uric-acid-lowering agent, FebuxOstat on subclinical inflammation in patients with hyperuricemia (UFO study)hyperuricemiaJPRN-UMIN000009262FO study Investigators100
招募中
3 期
the effect of febuxostat in sepsisIRCT20230814059148N1Tabriz University of Medical Sciences40
已完成
不适用
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia in chronic kidney disease.Hyperuricemic patients with CKDJPRN-UMIN000005573Yokohama City University Medical Center40
已完成
不适用
A study to evaluate the effect of febuxostat in heart failure patients with hyperuricemiaHeart failureJPRN-UMIN000021919Kochi Medical School, Kochi University200